The 105th American Association for Thoracic Surgery (AATS) Annual Meeting in Seattle, 2025, marked an exciting and meaningful moment for Genesee BioMedical, Inc. As one of the most prestigious global gatherings in cardiothoracic surgery, AATS brings together leaders from across the field to share research, discuss evolving techniques, and help shape the future of cardiac surgery.
Pictured from left to right: Nate Hansen, Director of Sales, Anthony Ferrante, Woody Mathison, and Matt Dambeck, CEO
This year’s meeting carried special significance, as it also marked the first major industry event for Genesee BioMedical’s new Chief Executive Officer, Matt Dambeck. Attending AATS together made the meeting not only an important scientific forum, but also the beginning of a new chapter for the company.
Engaging with the Global Cardiac Surgery Community
Throughout the meeting, conversations reflected the breadth and depth of the AATS audience. Surgeons from around the world gathered to exchange perspectives on surgical practice, emerging technologies, and the evolving needs of patients and care teams.
For Genesee BioMedical, AATS provided an important opportunity to engage with this global community. The team connected with long-standing partners, met new colleagues, and listened closely to how surgeons are thinking about the future of cardiac surgery.
The discussions were thoughtful and forward-looking, while remaining grounded in clinical reality. These exchanges reinforced the importance of staying aligned with surgeon experience and real-world application.
Pictured from left to right: Patrick McCarthy, MD, and Woody Mathison
A Milestone Moment for Genesee BioMedical, Inc.
Attending AATS alongside a new CEO underscored a sense of momentum and renewed focus for the organization. The meeting offered a valuable setting to introduce leadership, strengthen relationships, and engage in meaningful dialogue about where the field is heading and how innovation can continue to support surgical excellence.
Seattle served as the backdrop for conversations that extended beyond any single product or announcement. The focus remained on collaboration, long-term vision, and continued commitment to the cardiac surgery community.
Looking Forward
AATS 2025 served as both a reflection point and a forward-looking milestone. The conversations and connections made in Seattle continue to inform how Genesee BioMedical approaches engagement, innovation, and partnership across the field.
As the year progresses, the insights gained at AATS, alongside those from other key meetings, help shape the path ahead. We look forward to building on this momentum and continuing the dialogue with surgeons and clinical leaders at upcoming events.